Absci Corporation (ABSI) 株式分析

企業概要

Absci Corporation is a clinical-stage biopharmaceutical enterprise focused on the development of diverse antibody therapeutics within the United States, utilizing its preclinical and clinical programs to address unmet medical needs. The company operates within the Healthcare sector, specifically the Biotechnology industry, which typically involves high capital expenditure, prolonged research phases, and significant regulatory oversight before products reach commercialization. As of the latest data, the enterprise holds a market capitalization of $451.41M, generates annual revenue of $2.80M, and maintains an employee base of 140 individuals. These valuation and financial metrics indicate a small-cap biotechnology firm that is still in the early stages of its commercial lifecycle, where revenue generation is limited by the timing of clinical trial completions and regulatory approvals rather than established sales pipelines.

財務健全性

The company reported trailing twelve-month revenue of $2.80M alongside a net income loss of $-115,183,000, and an EBITDA loss of $-112,976,000, revealing a substantial gap between top-line sales and bottom-line profitability driven by heavy operational expenses and R&D costs. This wide disparity between revenue and net income highlights a cost structure typical of pre-commercial biotech firms, where research and development expenditures, personnel costs, and clinical trial expenses significantly outweigh current sales proceeds. The free cash flow stands at $-37,195,376, indicating that the company is burning cash rapidly to fund its development pipeline and has limited financial flexibility for external expansion or acquisitions without additional capital raising. Margin analysis shows a gross margin of 0.0%, an operating margin of -5452.6%, and a profit margin of 0.0%, reflecting that the current revenue does not yet cover the variable and fixed costs required to sustain operations at a loss. Despite the negative profitability metrics, the company holds cash reserves of $144.29M against total debt of $5.30M, resulting in a debt-to-equity ratio of 2.80, which suggests a balance sheet that is leveraged but heavily capitalized by cash liquidity. The current ratio of 6.57 indicates strong short-term liquidity, as current assets are more than six times current liabilities, providing a substantial buffer against immediate obligations. Furthermore, the return on equity is -62.5% and the return on assets is -36.3%, metrics that reveal that management is currently deploying capital to generate losses rather than positive returns, a common characteristic during the pre-revenue phase of biotechnology development.

バリュエーション評価

The valuation metrics present a complex picture for a loss-making biotechnology firm, with a trailing P/E ratio of N/A and a forward P/E of -4.71, implying that earnings are currently negative and any forward projection relies on assumptions of future profitability that have not yet materialized. The price-to-book ratio is 2.36, suggesting that the market values the company's equity at a premium of roughly 136% over its book value, likely reflecting the intangible value of its intellectual property and clinical pipeline rather than tangible assets. Alternative valuation measures such as the price-to-sales ratio of 161.22 and an EV/EBITDA of -2.77 indicate that investors are pricing the stock based on future growth potential and pipeline value rather than current earnings power or operational cash generation. The stock has traded within a range defined by a 52-week high of $5.23 and a 52-week low of $2.18, meaning the current share price sits somewhere within this volatility band but below the recent peak performance. The beta of 2.01 signifies that the stock's price volatility is twice that of the broader market, exposing investors to heightened risk and potential for larger swings in share price relative to market indices.

Growth & Income

The company experienced a revenue growth rate of -2.3% year-over-year, while earnings growth is marked as N/A due to the lack of positive earnings, indicating that the business is currently contracting in sales terms rather than expanding its top line. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings and cash flow are theoretically reinvested into research and development, though currently, the cash burn is funded by existing reserves rather than retained earnings. The absence of a dividend payout aligns with the company's lifecycle stage, where capital is prioritized for advancing clinical trials for programs like ABS-101 and ABS-201 rather than returning value to shareholders. Overall, the growth and income profile is characterized by negative revenue momentum, zero dividend income, and a capital-intensive strategy aimed at transitioning from preclinical or early clinical stages to commercial viability in the future.